Last Updated on July 1, 2026 by Dr. Bhagat
JOURNAL METRICS·Updated June 2026
Nature Cancer Impact Factor 2025 is 28.0 (Q1, Oncology, SCIE). Published by Springer Nature. Full JCR data and submission guide.
Key Takeaways
- Nature Cancer IF 2025 is 28.0 (Q1, Oncology, SCIE)
- Published by Springer Nature
- ISSN: 2662-1347 (Print) / 2662-1347 (Online)
Nature Cancer is a monthly research journal published by Springer Nature. Launched in January 2020, it publishes original research articles, reviews, and commentary spanning the full spectrum of cancer biology and oncology, from basic mechanistic insights to translational and clinical applications. Its 2024 Journal Impact Factor is 28.0, placing it in Q1 in the Oncology category.
Key Takeaways
- Impact Factor 2024: 28.0 (JCR Q1, Oncology)
- Publisher: Springer Nature, based in London, United Kingdom
- Launched: January 2020
- Publication frequency: Monthly
- Scope: Cancer biology, tumor immunology, cancer genomics, translational oncology, cancer therapeutics, and tumor microenvironment
OVERVIEWNature Cancer Journal Details
| Publisher | Springer Nature |
|---|---|
| ISSN | 2662-1347 |
| eISSN | 2662-1347 |
| Publication Frequency | Monthly |
| Language | English |
| Country | United Kingdom |
| First Issue | January 2020 |
| Subject Category | Oncology |
| Journal Type | Research Journal |
IMPACT FACTORNature Cancer Impact Factor 2024
The 2024 Journal Impact Factor for Nature Cancer is 28.0, as reported in the 2025 Journal Citation Reports (Clarivate). The journal ranks in Q1 within the Oncology category. Since its launch in 2020, Nature Cancer has rapidly become one of the most cited oncology journals, competing with established flagship publications in the field.
| Year | Impact Factor | JCR Category | Quartile |
|---|---|---|---|
| 2024 | 28.0 | Oncology | Q1 |
| 2023 | 23.5 | Oncology | Q1 |
| 2022 | 22.7 | Oncology | Q1 |
| 2021 | 21.0 | Oncology | Q1 |
SCOPUS METRICSNature Cancer CiteScore and SCImago
Nature Cancer is indexed in Scopus where it maintains a high CiteScore. The SCImago Journal Rank (SJR) reflects the journal’s rapid ascension in the oncology publishing landscape.
| Year | SCImago Journal Rank (SJR) |
|---|---|
| 2021 | 8.500 |
| 2022 | 9.200 |
| 2023 | 10.100 |
EDITORIAL FOCUSScope and Aims of Nature Cancer
Nature Cancer publishes research of the highest quality across all areas of cancer biology and oncology. The journal covers:
- Cancer biology and tumor genetics
- Tumor immunology and immunotherapy
- Cancer genomics, epigenomics, and systems biology
- Tumor microenvironment and metastasis
- Cancer metabolism
- Translational oncology and precision medicine
- Cancer therapeutics and drug resistance
- Cancer stem cells and developmental pathways
- Clinical research and trials
- Cancer prevention and early detection
PEER REVIEWNature Cancer Acceptance Rate and Review Process
Nature Cancer follows the rigorous editorial standards of all Nature Research journals. Submissions undergo initial editorial assessment for significance, originality, and technical quality before external peer review. The journal maintains a highly selective acceptance rate, publishing only research that represents a major conceptual or therapeutic advance in cancer science.
SUBMISSIONNature Cancer Submission Guidelines
Authors submit manuscripts through the Springer Nature online submission platform. The journal publishes original research articles, reviews, perspectives, and commentaries. All work must be original and not under consideration elsewhere. Article processing charges apply to accepted manuscripts.
| Submission to First Decision | ~7-10 days (initial editorial screening) |
|---|---|
| Peer Review Duration | ~45-60 days |
| Acceptance to Publication | ~15-30 days |
| Article Processing Charge | ~EUR 9,500 (research articles) |
INDEXINGAbstracting and Indexing
Nature Cancer is indexed in major bibliographic databases including:
- Science Citation Index Expanded (SCIE)
- Journal Citation Reports (JCR)
- Scopus
- PubMed/MEDLINE
- Google Scholar
CONTACTNature Cancer Editorial Office
The editorial office of Nature Cancer is located at Springer Nature’s headquarters in London, United Kingdom.
| Publisher | Springer Nature |
|---|---|
| Address | The Campus, 4 Crinan Street, London N1 9XW, United Kingdom |
| Country | United Kingdom |
| Website | nature.com/natcancer |
FAQSFrequently Asked Questions
What is the Impact Factor of Nature Cancer 2024?
The 2024 Impact Factor of Nature Cancer is 28.0, according to the 2025 Journal Citation Reports by Clarivate. It ranks in Q1 in the Oncology category.
Is Nature Cancer a Q1 journal?
Yes, Nature Cancer is a Q1 journal in the Oncology category according to the Journal Citation Reports (JCR).
Who publishes Nature Cancer?
Nature Cancer is published by Springer Nature, headquartered in London, United Kingdom.
When was Nature Cancer launched?
Nature Cancer was launched in January 2020 and has quickly become a leading venue for cancer research.
Is Nature Cancer indexed in PubMed?
Yes, Nature Cancer is indexed in PubMed/MEDLINE, Science Citation Index Expanded (SCIE), Scopus, and Google Scholar.
